Search

Displaying results 1891 - 1900 of 10000 in total
  1. Drug

    Lithium cation

    go.drugbank.com/drugs/DB01356
    ApprovedInvestigationalWithdrawn

    The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression.

    Synonyms: Lithium ion, Lithium, ion
  2. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    Commission on January 27, 2022. … [L39544] It was fully approved by the FDA on May 25, 2023.

  3. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860] … Niclosamide is an antihelminthic used for the treatment of tapeworm infections.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.

  5. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

  6. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

  7. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162] … [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e.

  8. Drug

    Cladosporium cladosporioides

    go.drugbank.com/drugs/DB10431
    Approved

    Cladosporium cladosporioides extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureCategories: Non-Standardized Fungal Allergenic Extract
  9. Drug

    Chloroquine

    go.drugbank.com/drugs/DB00608
    ApprovedInvestigationalVet approved

    [L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054] … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

    Categories: Analgesics, Non-Narcotic
  10. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial … [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma.

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE